Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Clinical Research and Equipment Industry Analysis

UpdatedDec 16, 2025
DataAggregated Company Financials
Companies7
  • 7D-3.8%
  • 3M-7.2%
  • 1Y-9.8%
  • YTDn/a

Over the last 7 days, the Clinical Research and Equipment industry has dropped 5.0%, driven by Lonza Group declining 6.2%. Overall the industry is down 11% in 12 months. Looking forward, earnings are forecast to grow by 20% annually.

Industry Valuation and Performance

Has the Swiss Clinical Research and Equipment Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 16 Dec 2025CHF 47.6bCHF 10.7bCHF 1.1b27.5x43.3x4.5x
Thu, 13 Nov 2025CHF 50.0bCHF 10.6bCHF 1.1b28.5x45.4x4.7x
Sat, 11 Oct 2025CHF 48.8bCHF 10.6bCHF 1.1b30.7x44.4x4.6x
Mon, 08 Sep 2025CHF 53.3bCHF 10.6bCHF 1.1b33.5x48.4x5x
Wed, 06 Aug 2025CHF 52.7bCHF 10.7bCHF 1.1b33.4x45.8x4.9x
Fri, 04 Jul 2025CHF 52.1bCHF 10.1bCHF 1.0b33.4x50.1x5.2x
Sun, 01 Jun 2025CHF 52.8bCHF 10.1bCHF 1.0b31.5x50.9x5.2x
Tue, 29 Apr 2025CHF 53.3bCHF 10.1bCHF 1.0b30x51.3x5.3x
Thu, 27 Mar 2025CHF 53.0bCHF 10.1bCHF 1.0b32.7x51.7x5.3x
Sat, 22 Feb 2025CHF 56.2bCHF 10.1bCHF 1.0b33x54.1x5.6x
Mon, 20 Jan 2025CHF 54.0bCHF 10.2bCHF 943.4m34.9x57.3x5.3x
Wed, 18 Dec 2024CHF 53.5bCHF 10.2bCHF 943.4m37.5x56.7x5.2x
Fri, 15 Nov 2024CHF 56.3bCHF 10.2bCHF 943.5m43x59.7x5.5x
Sun, 13 Oct 2024CHF 54.1bCHF 10.2bCHF 943.5m41.4x57.4x5.3x
Tue, 10 Sep 2024CHF 56.4bCHF 10.2bCHF 937.1m44.2x60.2x5.5x
Thu, 08 Aug 2024CHF 57.7bCHF 10.2bCHF 924.1m44.7x62.4x5.6x
Sat, 06 Jul 2024CHF 54.3bCHF 10.3bCHF 1.0b46.3x54.2x5.3x
Mon, 03 Jun 2024CHF 52.2bCHF 10.3bCHF 1.0b43.9x52.1x5.1x
Wed, 01 May 2024CHF 53.8bCHF 10.3bCHF 1.0b43.6x53.7x5.2x
Fri, 29 Mar 2024CHF 58.5bCHF 10.3bCHF 1.0b47x58.3x5.7x
Sun, 25 Feb 2024CHF 50.6bCHF 10.2bCHF 982.3m47.1x51.5x5x
Tue, 23 Jan 2024CHF 42.3bCHF 9.8bCHF 1.5b31.3x28.3x4.3x
Thu, 21 Dec 2023CHF 41.1bCHF 9.8bCHF 1.5b32.2x27.5x4.2x
Sat, 18 Nov 2023CHF 41.5bCHF 9.8bCHF 1.5b29.5x27.8x4.2x
Mon, 16 Oct 2023CHF 45.6bCHF 9.8bCHF 1.5b30.4x30.5x4.7x
Wed, 13 Sep 2023CHF 51.7bCHF 9.8bCHF 1.5b35x34.7x5.3x
Fri, 11 Aug 2023CHF 53.6bCHF 9.8bCHF 1.5b35.9x34.6x5.5x
Sun, 09 Jul 2023CHF 54.6bCHF 9.7bCHF 1.6b35.7x33.4x5.6x
Tue, 06 Jun 2023CHF 60.1bCHF 9.7bCHF 1.6b37.1x36.8x6.2x
Thu, 04 May 2023CHF 61.2bCHF 9.7bCHF 1.6b41.3x37.4x6.3x
Sat, 01 Apr 2023CHF 58.1bCHF 9.7bCHF 1.7b42x34.8x6x
Mon, 27 Feb 2023CHF 58.9bCHF 9.6bCHF 1.7b34.6x35.4x6.2x
Wed, 25 Jan 2023CHF 52.6bCHF 9.2bCHF 1.3b39.6x39.6x5.7x
Fri, 23 Dec 2022CHF 49.5bCHF 9.2bCHF 1.3b36.7x37.3x5.4x
Price to Earnings Ratio

37.3x


Total Market Cap: CHF 49.5bTotal Earnings: CHF 1.3bTotal Revenue: CHF 9.2bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Clinical Research and Equipment Industry Price to Earnings3Y Average 45.5x202320242025
Current Industry PE
  • Investors are relatively neutral on the Swiss Life Sciences Tools and Services industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 45.5x.
  • The 3-year average PS ratio of 5.2x is higher than the industry's current PS ratio of 4.4x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences Tools and Services industry have declined 6.1% per year over the last three years.
  • Meanwhile revenues for these companies have grown 5.1% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Comparison

How does Swiss Clinical Research and Equipment compare with similar industries?

CH Market0.45%
Healthcare0.49%
Life Sciences-3.76%
Clinical Research and Equipment-3.76%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SFZN Siegfried HoldingCHF 73.301.2%
+CHF 39.4m		-24.7%PE20.8x
PPGN PolyPeptide GroupCHF 24.801.6%
+CHF 13.2m		-15.9%PS2.4x

Latest News

BANB
CHF 53.40
Bachem Holding
7D
-0.3%
1Y
-17.1%

BANB Building K Expansion Will Define Future Upside And Execution Risk

Analysts have raised their price target for Bachem Holding from approximately CHF 58 to about CHF 75, citing increased confidence in revenue growth driven by the company's Building K expansion project, despite a slightly higher discount rate and modestly lower profit margin and valuation multiples. Analyst Commentary Recent research commentary highlights a more constructive stance on Bachem Holding, with the upgraded price target to CHF 75 framed around the growth potential from the Building K expansion project.
TECN
CHF 125.30
Tecan Group
7D
-4.9%
1Y
-39.2%

TECN: Medium Term Execution And CFO Transition Will Support Future Upside Potential

Analysts have lowered their price target on Tecan Group to CHF 170 from CHF 177, reflecting a slightly higher discount rate despite modestly improved revenue growth and profit margin expectations. Analyst Commentary Bullish analysts acknowledge the modest reduction in the price target but view the revised CHF 170 level as still supportive of upside potential from current trading levels, given improving fundamentals and execution.
SFZN
CHF 73.30
Siegfried Holding
7D
1.2%
1Y
-24.7%

SFZN: Incoming CFO Appointment Will Support Improved Profitability Prospects

Analysts have modestly revised their price target on Siegfried Holding higher to CHF 90.00 from CHF 90.00, reflecting slightly stronger expectations for revenue growth and profitability despite a mildly higher discount rate and a marginally lower future price to earnings multiple. What's in the News Siegfried Holding appointed Tania Micki as incoming Chief Financial Officer, effective July 1, 2026, succeeding long serving CFO Reto Suter, who has held the role since 2017 (company announcement).
SKAN
CHF 49.55
SKAN Group
7D
-1.9%
1Y
-31.4%
XLS
CHF 21.10
Xlife Sciences
7D
-9.1%
1Y
-18.8%
PPGN
CHF 24.80
PolyPeptide Group
7D
1.6%
1Y
-15.9%
LONN
CHF 523.20
Lonza Group
7D
-4.6%
1Y
-4.1%

We Think Lonza Group (VTX:LONN) Is Taking Some Risk With Its Debt

Dec 01
We Think Lonza Group (VTX:LONN) Is Taking Some Risk With Its Debt